{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:23:16Z","timestamp":1692332596303},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Many patients with severe asthma continue to have high symptom burden despite maximization of conventional therapy. As the understanding of asthma pathophysiology has evolved, however, more personalized therapy options have become available. Asthma biologics are a new class of medications that target the specific pathways that underlie a patient's disease and can reduce the frequency of asthma exacerbations and improve patient quality of life. Clinicians should refer potential candidates to a specialist for further evaluation.<\/jats:p>","DOI":"10.1097\/01.jaa.0000657220.41861.2d","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T04:19:34Z","timestamp":1590466774000},"page":"48-50","source":"Crossref","is-referenced-by-count":0,"title":["Treating asthma in the age of biologics"],"prefix":"10.1097","volume":"33","author":[{"given":"Anisha","family":"Prabakaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.anai.2015.12.024","article-title":"Elucidating asthma phenotypes and endotypes: progress towards personalized medicine","volume":"116","author":"Desai","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.anai.2018.07.033","article-title":"Selecting the right biologic for your patients with severe asthma","volume":"121","author":"Manka","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"26","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1513\/AnnalsATS.201703-259OC","article-title":"The economic burden of asthma in the United States, 2008-2013","volume":"15","author":"Nurmagambetov","year":"2018","journal-title":"Ann Am Thorac Soc"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000657220.41861.2d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T23:47:40Z","timestamp":1692316060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000657220.41861.2d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000657220.41861.2d","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}